Leave Your Message
ADT1013-Adebrelimab Biosimilar (B7-H1/PD-L1/CD274)-Research Biosimilar Antibody
Antibody

ADT1013-Adebrelimab Biosimilar (B7-H1/PD-L1/CD274)-Research Biosimilar Antibody

  • Catalog Number ADT1013
  • Host CHO Cells
  • Species Mouse
  • Target B7-H1/PD-L1/CD274
  • Application ELISA, FCM, BLI, SPR, Functional assay

Our expert team focuses on optimizing expression systems and refining purification strategies to ensure the high quality of our biosimilar antibodies.

Products Categories
Featured Products
recommended service
quick links
Contact Us

Product Background

Programmed death-ligand 1 (PD-L1) also known as cluster of differentiation 274 (CD274) or B7 homolog 1 (B7-H1) is a protein that in humans is encoded by the CD274 gene.

Product Specification

Catalog Number

ADT1013

Product Name

ADT1013-Adebrelimab Biosimilar (B7-H1/PD-L1/CD274)-Research Biosimilar Antibody

Alternate Names

Recombinant Anti-PDL1 antibody,  PDL1 antibody,  CD274 antibody,  cd274 monoclonal antibody,  B7H1 antibody,  B7H1 monoclonal antibody,  PDL1 blocking antibody,  PDL1 blocking antibodies,  anti-PDL1 recombinant antibody,  PDL1 recombinant antibody,  B7H1 recombinant antibody

Clonity

Monoclonal

Host

CHO Cells

Species

Mouse

Target

B7-H1/PD-L1/CD274

Gene ID

60533

Isotype

IgG4SP Kappa

Size

100ug, 1mg, 5mg

Research Area

Cancer

CAS Number

2247114-85-6

Product Description

Anti-B7-H1 / PD-L1 / CD274 Reference Antibody (adebrelimab) is expressed from CHO. The heavy chain type is huIgG4SP,  and the light chain type is kappa. It has a predicted MW of 145.5 kDa.

Molecular Weight

145.5 KDa

Application

ELISA, Flow Cytometry, Kinetics (BLI), Kinetics (SPR), Functional assay

Purity

>95% as determined by SDS-PAGE

Concentration

batch dependent

Buffer

Supplied in PBS, PH7.5

Storage

Store at -20 °C for 12 months. Store at -80 °C for long term storage.

Shipping Condition

Shipped on ice packs.

Note

This product is for research use only.

Reference

1. Pardoll,  D. M. (2012). The blockade of immune checkpoints in cancer immunotherapy. Nature Reviews Cancer,  12(4),  252-264.
2. Topalian,  S. L.,  et al. (2012). Safety,  activity,  and immune correlates of anti-PD-1 antibody in cancer. New England Journal of Medicine,  366(26),  2443-2454.
3. Iwai,  Y.,  et al. (2002). PD-L1 (B7-H1) and PD-1 (CD279) pathway in cancer immunotherapy. Nature Reviews Immunology,  2(3),  227-238.